

## Financial Highlights

		FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Estimate FY2012 (Forecast as of Nov 2012)
Net sales	(Billions of yen)	928.5	955.9	1,084.3	1,127.6	1,154.6	881.5	892.6	1,200.0
	YoY	8.7%	3.0%	13.4%	4.0%	2.4%	2.4%	1.3%	3.9%
Operating income	(Billions of yen)	118.3	91.5	98.5	126.3	148.7	133.1	131.4	165.0
	YoY	29.3%	-22.6%	7.6%	28.2%	17.7%	29.3%	-1.3%	11.0%
Ordinary income	(Billions of yen)	124.1	96.1	109.1	128.4	152.1	135.0	140.8	170.0
	YoY	8.9%	-22.6%	13.5%	17.7%	18.5%	30.1%	4.4%	11.8%
Net income	(Billions of yen)	61.9	47.1	67.4	82.4	92.2	88.6	91.2	108.0
	YoY	17.0%	-23.9%	43.2%	22.1%	11.9%	26.8%	2.9%	17.2%
R&D expenses	(Billions of yen)	101.8	135.9	151.8	164.7	159.2	115.0	116.4	170.0
	YoY	-3.3%	33.5%	11.7%	8.4%	-3.3%	-5.7%	1.2%	6.8%
Overseas net sales	(Billions of yen)	385.2	395.0	525.5	552.5	579.7	428.2	434.2	603.0
	% of net sales	41.5%	41.3%	48.4%	49.0%	50.2%	48.6%	48.6%	50.2%

\* The above figures for fiscal years prior to FY2008 are the consolidated results of Otsuka Pharmaceutical Co., Ltd.

		FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Estimate FY2012 (Forecast as of Nov 2012)
Exchange rate									(Yen)
US\$		114.15	91.03	92.10	87.79	79.79	80.58	79.38	78.00
Euro		166.66	127.96	132.00	116.27	111.12	113.38	101.71	101.00

		FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Estimate FY2012 (Forecast as of Nov 2012)
Selling, general and administrative expenses									(Billions of yen)
Selling, general and administrative expenses		478.9	541.8	629.2	622.3	616.6	453.1	466.0	632.0
(% of net sales)		51.6%	56.7%	58.0%	55.2%	53.4%	51.4%	52.2%	52.7%
Promotion expenses		150.1	158.3	198.7	179.6	174.4	128.7	122.9	
Personnel expenses (including reserves)		78.6	85.7	96.7	97.9	99.8	73.1	76.2	
Advertising expenses		27.8	30.1	33.2	28.9	25.1	20.4	23.8	
Research and development expenses		101.8	135.9	151.8	164.7	159.2	115.0	116.4	170.0
(% of net sales)		11.0%	14.2%	14.0%	14.6%	13.8%	13.0%	13.0%	14.2%
R&D expenses of pharmaceuticals		96.5	131.9	141.6	153.4	149.3	107.6	109.9	160.0

		FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Estimate FY2012 (Forecast as of Nov 2012)
Capital expenditures									(Billions of yen)
Capital expenditures		58.6	63.4	62.5	44.8	43.3	27.9	38.4	45.0

		FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Estimate FY2012 (Forecast as of Nov 2012)
Depreciation									(Billions of yen)
Depreciation		32.3	40.3	46.6	48.1	48.1	35.4	33.6	48.0

### <Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Consolidated sales	<b>928.5</b>	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>881.5</b>	<b>892.6</b>	<b>1.3%</b>
Pharmaceutical business	640.3	651.7	715.9	751.1	782.2	586.9	606.7	3.4%
Japan	322.4	319.0	312.4	319.9	326.5	251.5	261.9	4.1%
North America	258.3	282.9	334.7	349.0	361.1	266.6	271.3	1.8%
Others	59.6	49.9	68.8	82.2	94.7	68.9	73.5	6.7%
Nutraceutical business	-	217.9	247.0	256.4	251.3	200.7	192.3	-4.2%
Japan	-	163.9	142.6	154.1	147.4	123.0	117.5	-4.5%
North America	-	38.8	47.1	46.8	45.8	32.3	34.2	6.0%
Others	-	15.2	57.3	55.6	58.1	45.4	40.6	-10.6%
Consumer products business	258.6	51.9	50.1	47.1	48.0	39.1	36.8	-6.0%
Japan	193.0	45.7	44.1	40.9	42.0	34.4	32.0	-7.0%
North America	51.1	6.2	5.4	5.5	5.4	4.3	4.3	-0.3%
Others	14.6	0.0	0.6	0.7	0.6	0.5	0.6	15.1%
Other business	29.6	34.4	71.3	72.9	73.1	54.8	56.9	3.8%
Japan	27.9	32.4	59.7	60.1	59.1	44.4	47.0	5.8%
North America	0.2	0.4	1.3	1.4	1.3	1.0	1.0	0.3%
Others	1.5	1.6	10.4	11.4	12.7	9.3	8.8	-5.6%
Japan -total	543.3	560.9	558.8	575.1	574.9	453.3	458.3	1.1%
North America - total	309.6	328.3	388.4	402.7	413.5	304.1	310.8	2.2%
Others - total	75.6	66.7	137.1	149.8	166.2	124.1	123.4	-0.5%
Overseas net sales	385.2	395.0	525.5	552.5	579.7	428.2	434.2	1.4%
Overseas net sales ratio	41.5%	41.3%	48.4%	49.0%	50.2%	48.6%	48.6%	

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Net Sales and Operating Income by Geographical and Business Segment

### (1) Geographical segment

(Billions of yen)

	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Net sales	<b>928.5</b>	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>881.5</b>	<b>892.6</b>	<b>1.3%</b>
Japan*	643.1	689.0	709.4	745.2	779.1	597.6	607.7	1.7%
North America*	314.4	315.0	406.2	426.0	437.5	320.6	333.7	4.1%
Others*	66.4	55.6	121.6	132.5	142.4	109.8	102.5	-6.6%
Eliminations/corporate	-95.4	-103.6	-152.8	-176.2	-204.4	-146.5	-151.4	

\*Intersegment sales are included.

(Billions of yen)

	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Operating income	<b>118.3</b>	<b>91.5</b>	<b>98.5</b>	<b>126.3</b>	<b>148.7</b>	<b>133.1</b>	<b>131.4</b>	<b>-1.3%</b>
Japan	101.2	73.8	86.5	106.3	142.5	120.3	119.1	-1.0%
North America	9.8	9.9	11.3	12.2	14.4	10.2	6.3	-38.4%
Others	8.0	5.2	8.4	6.8	3.7	5.2	6.1	15.8%
Eliminations/corporate	-0.8	2.6	-7.7	1.0	-12.0	-2.7	-0.1	

### (2) Business segment

(Billions of yen)

	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Net sales	<b>928.5</b>	<b>955.9</b>	<b>1,084.3</b>	<b>1,127.6</b>	<b>1,154.6</b>	<b>881.5</b>	<b>892.6</b>	<b>1.3%</b>
Pharmaceutical business*	640.9	652.2	715.9	751.1	782.2	586.9	606.7	3.4%
Nutraceutical business*	-	219.2	248.8	258.7	254.8	203.3	195.8	-3.7%
Consumer products business*	258.8	52.1	51.1	47.9	49.2	40.0	37.9	-5.4%
Other business*	51.9	60.1	105.1	106.9	108.6	82.5	85.4	3.4%
Eliminations/corporate	-23.2	-27.6	-36.6	-37.0	-40.3	-31.2	-33.1	

\*Intersegment sales are included.

(Billions of yen)

	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Operating income	<b>118.3</b>	<b>91.5</b>	<b>98.5</b>	<b>126.3</b>	<b>148.7</b>	<b>133.1</b>	<b>131.4</b>	<b>-1.3%</b>
Pharmaceutical business	127.6	133.6	132.9	142.8	168.5	139.6	141.7	1.6%
Nutraceutical business	-	-5.2	2.3	18.4	22.1	23.4	17.3	-26.3%
Consumer products business	2.4	-3.7	-8.4	-2.2	-2.3	-1.2	-1.4	-
Other business	1.9	2.3	4.4	4.4	1.9	1.8	4.3	131.0%
Eliminations/corporate	-13.6	-35.5	-32.7	-37.1	-41.6	-30.5	-30.4	

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

## Product sales - Pharmaceutical business

(Billions of yen)

Products	Company	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change	Estimate FY2012 (Forecast as of Nov 2012)
Antipsychotic agent <i>ABILIFY</i>	Otsuka Pharmaceutical	273.8	297.1	374.5	392.6	411.6	303.7	309.8	2.0%	415.0
North America		231.1	237.2	305.6	308.3	316.1	232.7	236.6	1.7%	320.0
<US\$ million>		<2,025>	<2,606>	<3,303>	<3,512>	<3,960>	<2,884>	<2,979>	3.3%	<4,100>
Japan		8.7	13.2	18.8	23.0	24.8	18.9	22.2	17.5%	28.5
Others		34.0	46.7	50.1	61.2	70.7	52.1	51.0	-2.2%	66.5
Anti-platelet agent <i>Pletaal/Pletal</i>	Otsuka Pharmaceutical	47.1	46.6	51.5	53.2	50.3	39.3	35.7	-9.1%	46.0
Japan		40.3	42.1	45.4	46.5	44.1	34.5	31.3	-9.1%	40.5
Others		6.8	4.5	6.1	6.7	6.2	4.8	4.4	-8.6%	5.5
Anti-gastritis and anti-gastric ulcer agent <i>Mucosta</i>	Otsuka Pharmaceutical	38.8	38.3	37.1	30.7	28.7	22.7	18.1	-20.3%	24.0
Japan		35.3	36.2	34.5	27.8	26.0	20.6	16.2	-21.5%	21.5
Others		3.5	2.1	2.6	2.9	2.7	2.1	1.9	-8.6%	2.5
Anti-metabolite <i>TS-1</i>	Taiho Pharmaceutical	37.2	46.0	37.3	37.1	36.5	28.6	28.5	-0.3%	38.0
Anti-metabolite <i>UFT</i>	Taiho Pharmaceutical	25.0	25.6	18.3	15.7	12.9	10.4	8.8	-15.0%	10.5
Reduced folic acid formulation <i>Uzel</i>	Taiho Pharmaceutical	15.7	17.7	15.2	14.1	12.7	10.0	10.2	1.8%	13.0
Urinary incontinence / frequency treatment <i>P4 (BUP-4)</i>	Taiho Pharmaceutical	10.7	10.0	7.6	7.0	6.3	5.1	4.5	-12.5%	6.5
Oral nutrient for liver failure <i>Aminoleban EN</i>	Otsuka Pharmaceutical	6.4	6.2	6.4	6.5	6.1	4.8	4.5	-7.0%	6.0
Bronchodilator <i>Meptin</i>	Otsuka Pharmaceutical	6.6	6.1	5.9	6.1	5.7	4.5	4.1	-8.1%	5.5
H <sub>2</sub> -receptor antagonist <i>Protecadin</i>	Taiho Pharmaceutical	4.3	6.0	5.1	5.8	6.3	5.0	4.7	-6.7%	6.5
5-HT <sub>3</sub> receptor antagonist <i>Aloxi</i>	Taiho Pharmaceutical				4.3	7.9	6.0	7.7	29.2%	10.5
Antineoplastic <i>Abraxane</i>	Taiho Pharmaceutical				1.1	3.2	2.5	2.8	14.2%	4.0
Antiepileptic <i>E Keppra</i>	Otsuka Pharmaceutical				0.8	4.8	3.3	7.9	143.3%	10.5
V <sub>2</sub> -vasopressin receptor antagonist <i>Samsca</i>	Otsuka Pharmaceutical			0.6	3.2	6.7	4.7	8.8	88.0%	12.0
Anticancer <i>SPRYCEL</i> (collaboration with BMS)	Otsuka Pharmaceutical			2.0	8.0	7.6	5.7	6.4	12.5%	10.5
Antibiotic <i>Zosyn/Tazocin</i> (bulk supply)	Taiho Pharmaceutical	13.0	12.2	11.2	11.2	10.7	7.9	9.1	15.3%	11.0
Diagnostics -total	Otsuka Pharmaceutical	3.9	5.3	8.2	6.6	7.9	4.3	5.2	22.5%	7.5
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	90.6	89.8	92.9	96.8	96.0	73.4	75.2	2.5%	98.0
Japan		80.5	82.4	83.0	87.6	88.6	68.2	69.6	2.0%	90.5
Others		10.1	7.4	9.9	9.2	7.4	5.2	5.6	8.7%	7.5
Pharmaceutical business -total (excluding exports)	Japan	322.4	319.0	312.4	319.9	326.5	251.5	261.9	4.1%	340.0
Pharmaceutical business -total	Total	640.3	651.7	715.9	751.1	782.2	586.9	606.7	3.4%	820.0

\* The segment classification of quasi-drugs and nutritional products was changed from the pharmaceutical business to the nutraceutical business in July 2008.

\* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of the change in fiscal year end.

\* Net sales of *ABILIFY* for the calendar year ended 31 December 2012 was \$4,208 million (YOY 6.3%) at United States and Puerto Rico.

<Retrospective adjustments associated with changes in accounting policy>

From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

**Product sales - Nutraceutical business**

(10 thousand cases)

Products	Company	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		3,342	2,987	2,624	3,234	2,912	2,487	2,263	-9.0%
Overseas		1,224	1,650	1,884	1,597	1,963	1,492	1,619	8.5%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		262	303	187	113	100	83	71	-13.9%
Overseas		17	40	46	28	20	17	9	-47.5%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical, Otsuka Chemical	1,102	1,114	1,042	1,051	1,081	897	871	-2.9%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	417	387	396	392	351	275	264	-3.9%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	423	495	428	484	531	440	410	-6.8%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,722	1,928	1,591	1,571	1,578	1,318	1,314	-0.3%

\* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of a change in the fiscal year end.

\* Overseas sales include sales of consolidated subsidiaries only.

**Product sales - Consumer products business**

(10 thousand cases)

Products	Company	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	1,300	1,102	840	674	679	582	460	-21.0%
<i>NESCAFE</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	1,053	818	676	680	616	500	420	-16.0%
<i>Match</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	334	321	332	371	451	374	439	17.4%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	402	361	390	267	317	255	242	-5.1%

**Product sales - Other business**

(Billions of yen)

Products	Company	FY2007	FY2008	FY2009	FY2010	FY2011	FY2011 1-3Q	FY2012 1-3Q	Change
Functional chemicals	Otsuka Chemical	28.8	27.0	23.2	26.3	27.9	21.3	20.2	-5.3%
Fine chemicals	Otsuka Chemical	13.3	14.6	13.7	12.4	9.3	7.0	7.6	8.7%

Otsuka Group – Pipeline Information

(as of Dec 31, 2012)

Code/ Brand name	Generic name	Origin	Category	Indication/Dosage form	Country/Region	Development status
<b>Central nervous system</b>						
OPC-14597 (ABILIFY*)	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot injection	US, EU JP	Filed Phase III
				Adjunctive therapy for major depressive disorder / Oral	JP	Filed
				Autism / Oral	JP	Phase III
				Tourette's disorder / Once-weekly-Tablet	US	Phase III
				Bipolar I / Depot injection	US	Phase III
L059 (EKEPPRA*)	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (partial onset seizures for pediatric patients) / Oral	JP	Filed
				Epilepsy (generalized onset seizures) / Oral	JP	Phase III
				Epilepsy (partial onset seizures) / injection	JP	Phase III
				Epilepsy (partial onset seizures/mono therapy) / Oral	JP	Phase III
SPM-962 (Neupro patch)	rotigotine	UCB	Dopamine agonist	Parkinson's disease / Patch	JP	Approval
				Restless legs syndrome / Patch	JP	Approval
OPC-34712	brexiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US, EU	Phase III
				Schizophrenia / Oral	JP, US, EU	Phase III
				ADHD(Adults) / Oral	US	Phase II

## Otsuka Group – Pipeline Information

(as of Dec 31, 2012)

Code/ Brand name	Generic name	Origin	Category	Indication/Dosage form	Country/Region	Development status
<b>Anti-cancer and cancer-supportive care</b>						
ABI-007 (Abraxane)	paclitaxel protein-bound particle for injectable suspension	Celgene	Anti-cancer (nanoparticle )	NSCLC / Injection	JP	Filed
				Gastric cancer / Injection	JP	Filed
				Pancreatic cancer / injection	JP	Phase I / II
S-1 TS-1(Japan, Korea) TEYSUNO*(EU) TS-ONE*(Singapore) 愛斯万*(China) 愛斯萬*(Taiwan)	tegafur, gimeracil, oteracil potassium	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Gastric cancer / Oral	US	Phase III
				Uterocervical cancer / Oral	JP, Asia	Phase III
				Hepatocellular carcinoma / Oral	JP	Phase III
				Renal cell cancer / Oral	JP	Phase II
OVF	fentanyl citrate	Teva Pharmaceutical	Narcotic analgesic	Cancer pain / Buccal	JP	Filed
TSU-68	orantinib	(Sugen)	Anti-cancer (Molecular targeted drug)	Hepatocellular carcinoma / Oral	JP, Asia	Phase III
TAS-102		Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	JP, US, EU	Phase III
SATIVEX*	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OTS102	elpamotide	OncoTherapy Science	Therapeutic cancer vaccine	Biliary tract cancer / Injection	JP	Phase II
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
SPRYCEL	dasatinib	BMS	Anti-cancer	Pancreatic cancer / Oral	US,EU	Phase II
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Phase II
TAS-106		Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Solid tumors / Injection	US	Phase I / II
OPB-31121		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	US, JP, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	US	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP	Phase I

Otsuka Group – Pipeline Information

(as of Dec 31, 2012)

Code/ Brand name	Generic name	Origin	Category	Indication/Dosage form	Country/Region	Development status
<b>Cardiovascular</b>						
OPC-41061 (SAMSCA*)	tolvaptan	Otsuka Pharmaceutical	Vasopressin V <sub>2</sub> -receptor antagonist	Hepatic edema / Oral	JP, Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	JP, US, EU	Phase II - III**
				Cardiac edema / Oral	Asia	Phase III
				Carcinomatous edema / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
<b>Other areas</b>						
YP-18 (ZOSYN*)	tazobactam sodium-piperacillin sodium	Taiho Pharmaceutical	β-lactamase inhibitor-antibiotic agent	Febrile neutropenia / Injection	JP	Phase III
OPC-262 (ONGLYZA*)	saxagliptin	Bristol-Myers Squibb	DPP-IV inhibitor	Type2 diabetes mellitus / Oral	JP	Filed
OPC-67683	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	EU, JP, US	Filed Phase III
OPC-12759E (Mucosta Ophthalmic Suspension)	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops UD (Unit Dose)	US	Phase III
				Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
				Keratoconjunctival epithelial disorder / Eye drops UD (Unit Does)	JP	Phase II
OPB-2045G	gluconate olanexidin	Otsuka Pharmaceutical Factory	Antiseptics	Patient preoperative preparation / Topical	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
TAC-201		Meiji	Recombinant peptide for immunotherapy of Japanese cedar pollinosis	Cedar pollen allergy / Injection	JP	Phase II
ACU-4429		Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II
OPA-6566		Otsuka Pharmaceutical	Adenosine A2a receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
<b>Diagnostics</b>						
ODK-0902 (H. influenzae ELISA kit 「Otsuka」)	H. influenzae ELISA kit	Otsuka Pharmaceutical	Diagnostic aid for H. influenzae infection	In-vitro diagnostic agent	JP	Approved
ODK-1003 (WT1 mRNA Assay Kit II "Otsuka")	Wilms tumor-1 gene (WT1) mRNA measurement KIT	Otsuka Pharmaceutical	Diagnostic aid for AML( acute myeloid leukemia) ,MDS(myelodysplastic syndrome)	In-vitro diagnostic agent	JP	Filed

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "\*" are the names used outside Japan.

Note 3: \*\* Preparation for additional study.